Phase 2 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old and have been identified as having early (prodromal) Parkinson's disease, and have already been confirmed eligible for a related study baseline visit called the PPMI Clinical Baseline visit.
- You are able to understand and sign a consent form agreeing to take part in the trial.
- If you are a woman who could become pregnant, you must be using a highly effective form of birth control (such as the pill for at least 3 months, an IUD for at least 2 months, or a barrier method like a diaphragm or condom plus spermicide) starting at least 14 days before and until at least 24 hours after receiving the study injection — note that methods like tracking your cycle are not accepted under this trial's rules.
- If you are a woman who cannot become pregnant — either because you have gone through menopause (no periods for at least 12 months) or have had a surgical procedure such as removal of the ovaries, fallopian tubes, or uterus — you are also eligible on this point.
Who may not be able to join:
- You have taken certain medications — including tetrabenazine, methylphenidate, reserpine, or amphetamine-based drugs — within the last month before the study scan, as these could interfere with the imaging used in the trial.
- You have another medical or mental health condition, or an abnormal lab result, that the trial doctor believes would make it unsafe or unsuitable for you to participate (confirm with trial site).
- You are a woman who is currently pregnant, breastfeeding, or nursing, or who tests positive on a pregnancy test on the day of the scan.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ken Marek, MD, Institute for Neurodegenerative Disorders
Phone: 203-590-5600
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
[18F]AV-133 mean rate of change and variability
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.